Study drug for vulvar cancer after prior treatment failure
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests AK104 in people with recurrent or metastatic vulvar cancer that cannot be cured with surgery or strong radiation. It may help shrink tumors or slow growth, especially if you’ve already tried standard treatments or couldn’t tolerate them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 80 years old.
- You have vulvar cancer confirmed on biopsy as squamous cell or adenosquamous type.
- Your cancer can’t be cured with surgery or radical radiation.
- Your cancer has measurable tumor spots on scans.
- You’ve had at least one prior cancer medicine that either stopped working or you couldn’t tolerate.
- You must be able to use effective birth control if you could become pregnant, and have a negative pregnancy test before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well carboplatin plus paclitaxel chemotherapy works for vulvar squamous cell cancer that has spread. It may help shrink tumors and control cancer growth in people who are not able to be fully treated with local surgery.
This trial tests giving chemotherapy (carboplatin and paclitaxel) before surgery for certain cases of squamous cell vulvar cancer. It may help shrink the tumor and make surgery more effective.
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
This trial tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for women with advanced vulvar cancer that cannot be surgically removed or has spread. The goal is to see if this combination can shrink or control the cancer.
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
This trial tests a new drug called AK104 combined with standard chemotherapy and either cetuximab or bevacizumab for people with metastatic colorectal cancer that cannot be surgically removed. It is for those who have had only one prior line of treatment and whose tumors are not MSI-H or have a BRAF mutation.
Hear when a new Vulvar Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.